Arca
Skip to content
Tools
Tools

DPP4: Dipeptidyl peptidase 4

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T- cell activation.

  • Drugs that act on it: 17
  • Approved: 11
  • In phases 1 to 3: 6
  • Sponsors: 17

Who Is On It, and How Far Along

Every drug ChEMBL records acting on DPP4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody

Approved11

  • Sitagliptin
  • Linagliptin
  • Vildagliptin
  • Alogliptin
  • Trelagliptin
  • Anagliptin
  • Evogliptin
  • Gosogliptin
  • Omarigliptin
  • Saxagliptin anhydrous
  • Teneligliptin

Phase 34

  • Begelomab
  • DBPR-108
  • Dutogliptin
  • Gemigliptin

Phase 22

  • Bisegliptin
  • Carmegliptin

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • ActivX Biosciences, Inc.16%
    • Chong Kun Dang Pharmaceutical16%
    • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.16%
    • Dong-A ST Co., Ltd.16%
    • Getz Pharma16%
    • Handok Inc.16%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule1694%
    • Antibody16%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Dipeptidyl peptidase IV inhibitor.
    SitagliptinApprovedChong Kun Dang PharmaceuticalSmall moleculeInhibitor—28—
    LinagliptinApprovedBoehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor—17—
    VildagliptinApprovedGetz PharmaSmall moleculeInhibitor—7—
    AlogliptinApprovedCelltrionSmall moleculeInhibitor—5—
    TrelagliptinApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor—3—
    AnagliptinApprovedJW PharmaceuticalSmall moleculeInhibitor—1—
    EvogliptinApprovedDong-A ST Co., Ltd.Small moleculeInhibitor—0—
    GosogliptinApprovedPfizerSmall moleculeInhibitor—0—
    OmarigliptinApprovedMerck & Co. (MSD)Small moleculeInhibitor—0—
    Saxagliptin anhydrousApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor—0—
    TeneligliptinApprovedHandok Inc.Small moleculeInhibitor—0—
    BegelomabPhase 3AdienneAntibodyInhibitor—0—
    DBPR-108Phase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Small moleculeInhibitor—0—
    DutogliptinPhase 3PhenomixSmall moleculeInhibitor—0—
    GemigliptinPhase 3LG ChemSmall moleculeInhibitor—0—
    BisegliptinPhase 2ActivX Biosciences, Inc.Small moleculeInhibitor—0—
    CarmegliptinPhase 2RocheSmall moleculeInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov.
    Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 DiabetesSitagliptinPhase 2RecruitingUniversitas Sriwijaya2026-11-10
    A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseLinagliptin, Alogliptin, SitagliptinPhase 2Active, not recruitingBeijing University of Chinese Medicine2026-10-30
    Cardioprotection Effect of LinagliptinLinagliptinPhase 3Not yet recruitingTanta University2026-10-01
    Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary SyndromeVildagliptinPhase 2 / Phase 3Not yet recruitingTanta University2026-09-09
    Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's DiseaseSitagliptinPhase 2Not yet recruitingYonsei University2026-09-04
    Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerSitagliptinPhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2026-07-21
    Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentSitagliptinPhase 4RecruitingFudan University2026-07-17
    PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCTSitagliptinPhase 1 / Phase 2RecruitingNorthwell Health2026-06-30
    New Triple Combination Therapy in Newly Diagnosed Type 2 DiabetesLinagliptinPhase 3Not yet recruitingSun Yat-sen University2026-06-09
    Sitagliptin With Pembro in RCC and MelanomaSitagliptinPhase 1RecruitingFernando Maciel Barbosa2026-06-08
    Sitagliptin in Recurrent/Progressive Grade 4 GliomaSitagliptinPhase 1RecruitingKailin Yang, MD, PhD2026-04-21
    Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesLinagliptinPhase 4Enrolling by invitationBahria University2026-03-05
    Glycemic Variability of Combination Therapies in T2DMLinagliptin, AnagliptinPhase 4RecruitingJW Pharmaceutical2026-03-02
    The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLDAlogliptinPhase 4Not yet recruitingThe Fourth Affiliated Hospital of Zhejiang University School of Medicine2025-12-17
    Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 DiabetesLinagliptin—Not yet recruitingYanbing Li2025-09-30
    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Linagliptin, Alogliptin—Active, not recruitingOhio State University2025-09-23
    Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminAlogliptinPhase 3RecruitingCelltrion2025-07-30
    Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic PatientsTrelagliptinPhase 3Enrolling by invitationKhyber Medical College, Peshawar2025-07-18
    A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State StudyLinagliptinPhase 1Not yet recruitingAJU Pharm Co., Ltd.2025-07-01
    Clinical Trial of Vildagliptin in Early Parkinson's DiseaseVildagliptinNot applicableNot yet recruitingFirst Affiliated Hospital, Sun Yat-Sen University2025-04-30
    Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesTrelagliptin, VildagliptinNot applicableActive, not recruitingPNS Hafeez - Naval Hospital2025-04-06
    Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesTrelagliptin, VildagliptinNot applicableActive, not recruitingLahore General Hospital2025-03-21
    Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary SyndromeVildagliptinPhase 2 / Phase 3RecruitingOctober 6 University2023-11-21
    Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes MellitusVildagliptinPhase 4Active, not recruitingNational Center for Global Health and Medicine, Japan2022-05-09
    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyAlogliptin—Active, not recruitingBrigham and Women's Hospital2022-02-02
    Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DMVildagliptinPhase 3RecruitingSherief Abd-Elsalam2019-04-24

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Type 2 diabetes mellitus
    0.64
    Neurodegenerative disease
    0.44
    Asthma
    0.42
    Type 1 diabetes mellitus
    0.41
    Smoking initiation
    0.41
    Kidney failure
    0.40
    Intelligence
    0.39
    Stroke disorder
    0.39

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL284, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P27487, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.